Skip to main content
. Author manuscript; available in PMC: 2013 Jun 14.
Published in final edited form as: Leuk Lymphoma. 2011 Jan 28;52(4):587–596. doi: 10.3109/10428194.2010.543714

Table II.

Reasons for discontinuation of treatment.

Reason treatment terminated No. of patients %
Completed treatment 52 63.4%
Adverse event 10 12.2%
Catheter problems 10 12.2%
Patient withdrawal 6 7.3%
HAMA/HARA positive 2 2.4%
Disease progression 1 1.2%
Study closure 1 1.2%

HAMA/HARA, human anti-mouse antibody/human anti-ricin antibody.